HomeIBRX • NASDAQ
Immunitybio Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 16.52M | 41,192.50% |
Operating expense | 80.89M | -15.07% |
Net income | -129.65M | 3.33% |
Net profit margin | -784.92 | 99.77% |
Earnings per share | -0.15 | — |
EBITDA | -60.60M | 33.14% |
Effective tax rate | 0.18% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 61.59M | -63.88% |
Total assets | 303.76M | -24.19% |
Total liabilities | 894.24M | -18.08% |
Total equity | -590.48M | — |
Shares outstanding | 882.62M | — |
Price to book | -3.87 | — |
Return on assets | -46.91% | — |
Return on capital | -60.35% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -129.65M | 3.33% |
Cash from operations | -85.91M | 19.70% |
Cash from investing | 4.13M | 111.59% |
Cash from financing | -982.00K | -109.60% |
Net change in cash | -82.77M | 37.49% |
Free cash flow | -63.34M | 6.69% |
Previous close
$2.67
Day range
$2.67 - $2.88
Year range
$1.83 - $8.07
Market cap
2.54B USD
Avg Volume
9.20M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
CEO
Founded
2014
Website
Employees
671
